Print this page
-
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia.
Protocol: 022404-MM1YA-S01Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination with ASTX727 in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Protocol: 022503Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other
Myeloid and Monocytic Leukemia -
Phase 3 Randomized, Double-Blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax + Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia.
Protocol: 022501Principal Investigator:
- Xiaoyi Chen
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study Of Olverembatinib (HQP 1351) In Patients With Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Protocol: 022504Principal Investigator:
- Adam Zayac
Applicable Disease Sites: Leukemia, not otherwise specified -
A Phase I Study of Autophagy Inhibition with Hydroxychloroquine and Oral Decitabine with Venetoclax after Hypomethylating Agent and Venetoclax Failure in Acute Myeloid Leukemia.
Protocol: 022601Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, not otherwise specified
Leukemia, other -
A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Protocol: 022602Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, not otherwise specified
Leukemia, other -
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination with ASTX727 in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Protocol: 022503Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other
Myeloid and Monocytic Leukemia -
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study Of Olverembatinib (HQP 1351) In Patients With Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Protocol: 022504Principal Investigator:
- Adam Zayac
Applicable Disease Sites: Leukemia, not otherwise specified -
A Phase I Study of Autophagy Inhibition with Hydroxychloroquine and Oral Decitabine with Venetoclax after Hypomethylating Agent and Venetoclax Failure in Acute Myeloid Leukemia.
Protocol: 022601Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, not otherwise specified
Leukemia, other -
A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Protocol: 022602Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, not otherwise specified
Leukemia, other -
Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia.
Protocol: 112002Principal Investigator:
- Peter D. Cole
Applicable Disease Sites: Leukemia, not otherwise specified -
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
Protocol: 112008Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, not otherwise specified -
Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia.
Protocol: 112002Principal Investigator:
- Peter D. Cole
Applicable Disease Sites: Leukemia, not otherwise specified -
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
Protocol: 112008Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, not otherwise specified -
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Leukemia, not otherwise specified -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.
Protocol: 112305Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Hodgkin's Lymphoma